FDA Approves First-in-Class Blood Cancer Drug as New Breast Cancer Resistance Mechanism Discovered

The FDA approved rusfertide (Mimrylo), a first-in-class drug for polycythemia vera (PV), a rare blood cancer affecting 150,000 U.S. patients, marking a significant advance for a condition with few targeted treatment options.

Plain English

Think of polycythemia vera as your body producing too much blood, like a faucet stuck in the "on" position. This new weekly injection mimics a natural hormone to help turn down that production, reducing dangerous blood clots and the...